Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2011

View Archived Issues

HspB8 blocks autophagy in breast cancer cells, conferring resistance to tamoxifen

AV-7909 improves survival of ciprofloxacin-treated guinea pigs exposed to B. anthracis

AB-103 protects mice from SEB- and LPS-induced lethal shock

Bakuchiol cream is efficacious against acne in open-label trial

Etanercept demonstrates little activity to date in phase II trial in discoid lupus erythematosus

BAY-86-4367 effectively targets prostate tumors in preclinical study

Gentium completes defibrotide studies in veno-occlusive disease and prepares regulatory filings

GSK to launch new alli chewable tablet as weight loss aid

Phase IIb trial to compare delafloxacin to linezolid and vancomycin in ABSSSI

EMA grants orphan drug status to GT-038 in retinitis pigmentosa

Treatment begins in phase I elesclomol trial in acute myeloid leukemia

CytRx reports preclinical data on bafetinib in cancer-related bone loss

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

R-Tech Ueno begins phase I trial to test RL-023's safety as therapy for eyelash hypotrichosis

Clinuvel completes phase II Scenesse trial in erythropoietic protoporphyria

Biovail Labs acquires Canadian license for Aczone from Allergen

Pervasis Therapeutics' Vascugel receives FDA fast track status

AMAG receives NON from Health Canada regarding Feraheme submission

Johnson & Johnson reports highlights fourth quarter 2010

Circassia acquires worldwide rights to psoriasis and atopic dermatitis treatment PAP-1

A.P. Pharma provides company update

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...